Drug-coated Balloon Angioplasty For Ischemic Stroke Within 30 Days Caused By Intracranial Arterial Stenosis ( BASIS-2 )
Key facts
- Who runs it
- Beijing Tiantan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 360 people, planned
- Started
- 6 Nov 2026
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Drug therapy administration
- Intracranial artery balloon dilatation combined with intensive medical treatment
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (26)Hide the full registry criteria
Who can take part
- Older than 18 years old, regardless of gender
- Patients with ischemic stroke caused by intracranial artery stenosis within 30 days of onset
- Responsible intracranial artery (including anterior circulation and posterior circulation. The lesions of anterior circulation and posterior circulation include: the end of internal carotid artery (C4-C7 segment), middle cerebral artery M1 segment, vertebral artery V4 segment and basilar artery) stenosis degree is between 70% and 99% (MRA/CTA/DSA judgment)
- One of the following conditions shall be met for the combination of hypoperfusion in the blood supply area of the responsible artery, poor collateral compensation or watershed infarction:; 1)Ischemic stroke still occurred after intensive medical treatment 2)Brain perfusion CT showed that the cerebral blood flow decreased by ≥ 30% in anterior circulation lesions compared with contralateral cerebral perfusion and posterior circulation lesions compared with ipsilateral anterior circulation 3)Under digital subtraction angiography (DSA), the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) score was less than 3 points 4)Brain magnetic resonance imaging (MRI) showed hemodynamic ischemic lesions 5)Single photon emission computed tomography (SPECT) showed cerebral hypoperfusion 5.mRS ≤ 1 point before onset 6.Study population who voluntarily participated in the study and signed the informed consent
Who cannot take part
- Those who have undergone surgery within 30 days or plan to undergo major surgery within 90 days (surgical grade is grade III or above)
- Previous angioplasty (including balloon dilatation, stent implantation or endarterectomy) or planned stent implantation on the target vessel or its main supplying artery
- Those who are participating in clinical trials of other drugs/devices and have not completed all follow-up required by the protocol
- Stroke caused by perforator occlusion (except for severe stenosis of the feeding artery with hemodynamic damage or poor collateral circulation)
- Anterior circulation stroke: ASPECTS score<6; Posterior circulation stroke: pc-ASPECTS<6 or Pons Midbrain Index>2
- Non atherosclerotic diseases (such as arterial dissection, moyamoya disease, vasculitis caused by infection, autoimmune diseases, post irradiation and postpartum status; developmental or genetic abnormalities, such as fibromuscular dysplasia, sickle cell anemia, and suspected vasospasm)
- It is suspected that the ischemic event is due to embolism or arterial embolism from extracranial segment (including ipsilateral thoracic or cervical vascular occlusive disease) or potential cardiogenic embolism (such as atrial fibrillation, mitral stenosis, patent foramen ovale, left ventricular thrombosis, myocardial infarction within 6 weeks, etc.)
- Intracranial hemorrhage in the past 3 months, including cerebral parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage and subdural hemorrhage
- Those who cannot receive dual antiplatelet therapy due to other diseases
- Those who are allergic to heparin, aspirin, clopidogrel, ticagrelor, contrast agents, anesthetics and balloon components
- Those who cannot complete the follow-up due to mental disorders, cognitive or emotional disorders, etc
- Hemoglobin is less than 100g/L, platelet count is less than 100 × 10⁹/L, international normalized ratio (INR)>1.5 (irreversible), coagulation dysfunction or bleeding factors that cannot be corrected
- Severe liver and renal function damage, ALT > 3 times the upper limit of normal value or AST > 3 times the upper limit of normal value, serum creatinine > 2 times the upper limit of normal value
- Patients with intracranial artery stenosis>70% except the target vessel and its main blood supply artery
- If the main feeding artery of the target vessel has stenosis, the stenosis>50% should be excluded. For example, if the lesion is located in the middle cerebral artery, the ipsilateral internal carotid artery stenosis>50% should be excluded; When the lesion was located in the basilar artery, the dominant vertebral artery stenosis>50% should be excluded, and the non responsible extracranial artery>70% should be excluded; For balanced vertebral artery stenosis, if the contralateral vertebral artery has a stenosis of > 70% at the same time, it is excluded (because it is impossible to determine which side is the responsible vessel, and the contralateral stenosis also has the risk of potential vascular events). However, the contralateral vertebral artery ends in PICA, contralateral vertebral artery dysplasia or fibrosis, and the dominant vertebral artery is the responsible vessel of the main event can not be excluded from this exclusion range
- The target vessel has severe calcification and is closely related to stenosis
- Intracranial tumors, aneurysms or intracranial arteriovenous malformations
- The tortuous vascular path can not establish a stable vascular access
- Pregnant and lactating women
- Patients complicated with renal artery, iliac artery and coronary artery requiring simultaneous intervention were excluded
- The expected survival time is less than 1 year
- The researcher believes that the patient is not suitable to participate in this study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Intracranial atherosclerotic stenosis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a prospective, multicenter, randomized, open, parallel controlled clinical study initiated by researchers. The included population was patients with ischemic stroke. The primary end point was any new stroke (ischemic/hemorrhagic stroke) within 30 days after admission and all-cause death or ischemic stroke in the target vascular supply area within 31 days to 12 months after admission.
The 2 groups in the trial
- Standard medical treatmentExisting treatment, for comparison
Treatment: Drug therapy administration
- Intracranial artery durg-coated balloon dilatation combined with standard medical treatmentTreatment being tested
Treatment: Intracranial artery balloon dilatation combined with intensive medical treatment
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07931885, who can take part
- Record updated
- 12 November 2026